Passage Bio

Recently, our team had the opportunity to sponsor and participate in the AFTD "Driving Hope" golf tournament. We are honored to support AFTD’s crucial mission to enhance the quality of life for individuals impacted by FTD and drive research toward a cure.

This month, Passage Bio is participating in the Dementia Society of America’s #OperationKeepsafeChallenge—a 60-mile journey aimed at supporting individuals and families affected by dementia. We’re excited to kick off this challenge as a team! Learn more about #OperationKeepsafe and how you can get involved: https://loom.ly/NKM5A8c

As we continute to celebrate #WorldFTDAwareness Week, we’re happy to share that AFTD recently spoke with our Vice President of Clinical Development, Dr. Juan Chavez, about our efforts to develop a therapy for frontotemporal dementia. Dr. Chavez discusses the promising advancements in today’s research landscape and the vital role the #FTD community plays in driving therapeutic development. Learn more at the blog post here: https://loom.ly/R1h3Ybg #endFTD

This week, we had the privilege of welcoming Liz to our Philadelphia office, where she courageously shared her journey as a care partner to her mother who was diagnosed with #FTD. Her powerful story served as a poignant reminder of how critical it is to raise awareness about this often misunderstood and misdiagnosed disease. As we honor #FTDAwarenessWeek, we invite you to learn more about the most common form of dementia for people under 60: https://loom.ly/YR2UD8w We’re in this together. #endFTD

We’re proud to be participating in Chardan's 8th Annual Genetic Medicines Conference next week. Stay tuned for insights and updates from our leadership team as we continue to drive innovation in neurodegenerative conditions. Register to join our presentation here: https://loom.ly/mm9FmVM

This #WorldFTDAwarenessWeek, we’re not just raising awareness—we’re taking action. At Passage Bio, we’re deeply committed to advancing a promising treatment for frontotemporal dementia, and our ongoing clinical trial is a critical step toward making a real difference. Discover how we’re working to change lives: https://loom.ly/N9zzZxM #endFTD

Our employees recently gathered to celebrate our latest victories with an afternoon of bowling, ping pong, pool, and quality time with colleagues. As our CEO put it, "It's about celebrating the journey," and we made sure to do just that. Here's to the exciting milestones ahead!

We're excited to share positive data from Cohort 1 of our upliFT-D trial for #FTD-GRN patients, where #PBFT02 demonstrated robust and durable increases in CSF PRGN expression, maintained for up to a year. You can find more details at #ISFTD24 this week—visit Poster 007 if you're attending, or view the poster here: https://loom.ly/8Iwdvu8

AFTD spoke with Passage Bio Vice President of Clinical Development Juan Chavez, MD, about the company’s approach to developing a treatment for FTD-GRN. ?? Read the full interview here: https://bit.ly/47gtoJr

We’re excited to announce the appointment of Tom Kassberg to our Board of Directors. Tom, currently Chief Business Officer and Executive Vice President at Ultragenyx, brings extensive experience in strategic planning and corporate development to our organization. His expertise will be invaluable as we advance our mission to improve the lives of patients with neurodegenerative diseases. Read more here: https://loom.ly/Qeia90w